Shopping Cart

Remove All

Your shopping cart is currently empty

Dabuzalgron

Select Batch

Purity:98.47%

Resource Download

COA HPLC HNMR

Dabuzalgron

Catalog No. T10952Cas No. 219311-44-1

Dabuzalgron (Ro 115-1240) is an orally active selective alpha-1A adrenergic receptor agonist used to treat urinary incontinence. Dabuzaron prevents cardiotoxicity caused by doxorubicin by maintaining mitochondrial function.

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Pack Size	Price	Availability
1 mg	$53	In Stock
5 mg	$126	In Stock
10 mg	$228	In Stock
25 mg	$370	In Stock
50 mg	$555	In Stock
100 mg	$798	In Stock
1 mL x 10 mM (in DMSO)	$139	In Stock

Bulk & Custom

Add to Cart

Questions

Related Compound Libraries of "Dabuzalgron"

Product Introduction

Bioactivity

Description	Dabuzalgron (Ro 115-1240) is an orally active selective alpha-1A adrenergic receptor agonist used to treat urinary incontinence. Dabuzaron prevents cardiotoxicity caused by doxorubicin by maintaining mitochondrial function.
In vitro	Dabuzaron treatment increased ERK phosphorylation in a dose-dependent manner with an EC50 of 4.8 μM. ERK1 / 2 activation helps Dabuzaron's cardioprotection. Dabuzaron (10 μM; 4 hours) protects NRVM from cell death caused by doxorubicin (DOX). Dabuzaren (10 μM; 4 hours) activation of α1A-AR alleviates the harmful effects of DOX on mitochondrial membrane potential and eliminates the activation of important elements of the apoptotic response to mitochondrial damage.
In vivo	Dabuzaron (10μg / kg; oral tube; twice daily; 7 consecutive days; C57B16J wild-type or α1A-AR gene knockout mice) treatment can prevent DOX cardiotoxicity by activating α1A-AR. Dabuzaron prevents mitochondrial function-related transcript reduction, up-regulates PGC1α, retains ATP content, and reduces oxidative stress in DOX-treated mouse hearts.
Alias	Ro 115-1240

Chemical Properties

Molecular Weight	317.79
Formula	C12H16ClN3O3S
Cas No.	219311-44-1

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Solubility Information

DMSO: 25 mg/mL(78.67 mM)

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	3.1467 mL	15.7337 mL	31.4673 mL	157.3366 mL
5 mM	0.6293 mL	3.1467 mL	6.2935 mL	31.4673 mL
10 mM	0.3147 mL	1.5734 mL	3.1467 mL	15.7337 mL
20 mM	0.1573 mL	0.7867 mL	1.5734 mL	7.8668 mL
50 mM	0.0629 mL	0.3147 mL	0.6293 mL	3.1467 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:

For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments

A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent

DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。

Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO TargetMol | reagent

(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.

Preparation method for in vivo formula: Take 50 μL DMSO TargetMol | reagent

main solution, add 300 μLPEG300 TargetMol | reagent

mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O TargetMol | reagent

mix well and clarify

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc